Arch Therapeutics : LD Micro Invitational XI Presentation

Terrence W. Norchi, MD

Chief Executive Officer

Michael S. Abrams

Chief Financial Officer

Cautionary Statement Regarding Forward-Looking

Statements

This presentation includes forward-looking statements. We make forward-looking statements, as defined by the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, and in some cases, you can identify these statements by forward-looking words such as "if," "shall," "may," "might," "will likely result," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "goal," "objective," "predict," "potential" or "continue," or the negative of these terms and other comparable terminology. These include statements regarding: our ability to leverage our technology platform in the development of our lead and potential pipeline product candidates; our ability to design and conduct development activities and studies and clinical trials for our lead and potential pipeline product candidates; the potential timing and results of any such clinical trials we may conduct; our ability to obtain regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes in order to market any planned products; our ability to achieve financial projections; and our ability to achieve milestones. The forward-looking statements in this presentation are based on management's current expectations, estimates, forecasts and projections about the Company and its business, all of which could prove to wrong. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for our current and future fiscal years could differ materially from the Company's current expectations. Factors that could cause the Company's results to differ materially from those expressed in forward-looking statements include, without limitation, the following risks: we have estimated that we will have sufficient cash to operate our business for the near future, and we may not be able to obtain sufficient financing and/or establish necessary relationships with third parties to continue to pursue our business plan; the stockholder dilution that may result from future capital raising efforts and the exercise or conversion, as applicable of Arch's outstanding options and warrants; anti-dilution protection afforded investors in prior financing transactions that may restrict or prohibit Arch's ability to raise capital on terms favorable to the Company and its current stockholders; any development activities or clinical trials we may conduct may not produce favorable results; regulatory agencies may require that we undertake additional or more costly studies or clinical trials than we presently anticipate; we may never gain regulatory approval for any of our product candidates; we may not be able to protect our intellectual property rights; the intellectual property of others and any asserted claims of infringement; general business and economic conditions may limit our ability to obtain necessary capital; the consequences of competitive factors in the industry in which we operate may restrict the success of any product candidate we are able to commercialize, and we may not be able to attract or retain key personnel. More detailed information about us and the risk factors that may affect the realization of any forward-looking statements is set forth in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K filed on December 11, 2020 and subsequent filings with the SEC. Such documents may be read free of charge on the SEC's internet site at http://www.sec.gov. You are cautioned not to place undue reliance on any forward-looking statements we make in this presentation given these risks and uncertainties, and all such statements are qualified in their entirety by this cautionary statement. All forward-looking statements speak only as of the date hereof, and we undertake no obligation to revise or update any forward-looking statement to reflect events or circumstances after the date hereof, except as otherwise required by law.

2

Key Messages

Commercialization phase in progress

Breakthrough patented platform technology with multiple applications

Regulatory marketing authorization for initial products in US and EU

Critical inflection point in commercialization effort as hospitals reopen

Superior outcomes and value proposition supported by ongoing data collection

Robust product development pipeline targeting multiple market opportunities

Unique investment opportunity with compelling valuation

Arch Therapeutics and the AC5 name and design are registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.	3
Source: Arch Therapeutics, Inc., data on file. All images ©2013-2021 Arch Therapeutics, Inc., All Rights Reserved.

How Are We Reaching Our Goals?

With solid experienced leadership

Terrence W. Norchi, MD, MBA	Michael S. Abrams, MBA
Chairman, President, CEO, Founder	Chief Financial Officer
NEO Medical Univ, MIT, Tufts School of Med,	SharedLABS, QuantRx Biomedical, FitLife
Sanford Bernstein, Citigroup, Putnam	Brands, Burnham Hill Capital Group

James Sulat	Chirag Shah, PhD
Director	VP of R&D Engineering and Quality
Momenta, Valneva (Intercell), AMAG, Diadexus,	Covidien, Biolink, Bard
Chiron
Punit Dhillon	Daniel Wadsworth
Director	VP of Dermal Sciences
Oncosec, Inovio, Emerald Health Therapeutics	CR Bard, KCI, Medical Device Consulting

Arch Therapeutics and the AC5 name and design are registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.	4
Source: Arch Therapeutics, Inc., data on file. All images ©2013-2021 Arch Therapeutics, Inc., All Rights Reserved.

How Are We Reaching Our Goals?

And a "deep bench" of advisors

Shri Parikh

Mölnlycke, Stryker, St. Jude Medical, Bristol-Myers Squibb

Rutledge Ellis-Behnke, PhD

Medical Faculty Mannheim, Univ of

Heidelberg (Germany), MIT, Univ of

Hong Kong, Int'l Soc of Nanomedicine,

Glaucoma Foundation

Roger Gregory, PhD

Kent State University (past

Chairman of Department of

Chemistry), University of Sheffield,

England, University of Minnesota

Larry Hicks

American Optics, Drake Partners;

Past: Z-Medica, NeuroTherm,

Gyrus ACMI, Karl Storz Sports

Medicine, Endoscopy America

David Clarke

InfraScan, Drake Partners;

Past: Z-Medica, Olympus America,

American Cystoscope Makers,

B.Braun Medical, Pfizer

Arthur Rosenthal, PhD

Boston Scientific (past Chief

Scientific Officer), JNJ,

Boston University

John Richards, DPhil

Novartis (past SVP, Technical

R&D), The Medicines Company

(past President Global

Pharmaceutical Development),

ImmuLogic, ICI Pharma, Oxford

William Denman, MBChB, FRCA

Massachusetts General, Harvard

Medical School, Covidien (past Chief

Medical Officer), GE Healthcare

Steve Schwaitzberg, MD, FACS

Jacobs School of Medicine (U Buffalo SUNY), Cambridge Health Alliance, Tufts, Harvard Medical School, SAGES (past president)

Daniel Kapp, MD

Palm Beach Gardens Medical Ctr

(Chief of Plastic Surgery), Jupiter

Medical Wound Healing (Medical

Director), Recros Medica

Arch Therapeutics and the AC5 name and design are registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.	5
Current & past affiliations are listed above.